Overview
The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
Description
The goal of this pilot study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy. This is the first time investigators are examining this tool.
The U.S. Food and Drug Administration (FDA) has not approved DCOG Short as a mobile application tool to evaluate neurotoxicity for hematologic malignancies.
The research study procedures include screening for eligibility, questionnaires, and cognitive assessments.
It is expected that about 40 people will take part in this research study.
Eligibility
Inclusion Criteria:
- participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.
- Visual acuity of 20/100 or better.
Exclusion Criteria:
- patients \< 18 years old
- pregnant women
- prisoners
- adults unable to consent,
- participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad
